Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04843007 | Alvopem® (Pemetrexed) Safety Assessment | completed | — | 199 | NanoAlvandINDUSTRY | 0 | Oct 23, 2024 | clinicaltrials |
| NCT04007068 | FDG PET/CT Radiomics Analyses of Lung Cancer Patients Treated With Immunotherapy | completed | — | 30 | Institute of Oncology LjubljanaOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT02364609 |
| Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib |
| completed |
| Phase 1 |
| 11 |
| Jonathan RiessOTHER |
| 1 |
| Oct 16, 2024 |
| clinicaltrials |
| NCT03004183 | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC(STOMP) | completed | Phase 2 | 57 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05383898 | Study to Evaluate D-1553 in Subjects With Lung Cancer | completed | Phase 1 / Phase 2 | 225 | InventisBio Co., LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06313268 | Safety of Effivia®, a Bevacizumab Biosimilar | completed | — | 83 | Laboratorios LiomontINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02955758 | Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | completed | Phase 2 | 25 | Joel NealOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03526900 | Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis(ATEZO-BRAIN) | completed | Phase 2 | 40 | Spanish Lung Cancer GroupOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02775435 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | completed | Phase 3 | 559 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 8, 2024 | clinicaltrials |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03822351 | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC(COAST) | completed | Phase 2 | 189 | MedImmune LLCINDUSTRY | 9 | Oct 8, 2024 | clinicaltrials |
| NCT01899989 | Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer | completed | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05569291 | Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Cell Lung Cancer: an Explorative Study(LUCA-coach) | completed | N/A | 19 | Hasselt UniversityOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03875092 | A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | completed | Phase 3 | 125 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03718117 | Descriptive Observational Study ALK-2016-CPHG(ALK2016CPHG) | completed | — | 73 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03565003 | A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | completed | Phase 1 / Phase 2 | 126 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06607393 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | completed | — | 851 | Aetion, Inc.OTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT02578680 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | completed | Phase 3 | 616 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT02250326 | Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer(abound2L+) | completed | Phase 2 | 240 | CelgeneINDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT02358473 | Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer | completed | Phase 1 | 13 | Kyowa Kirin, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02855125 | A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 | completed | Phase 2 | 128 | Taiho Oncology, Inc.INDUSTRY | 6 | Sep 19, 2024 | clinicaltrials |
| NCT02864394 | Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) | completed | Phase 3 | 425 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 19, 2024 | clinicaltrials |
| NCT02927301 | A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) | completed | Phase 2 | 181 | Genentech, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04167657 | SinTilimab After Radiation (STAR Study)(STAR) | completed | Phase 2 | 14 | Peking Union Medical College HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04351334 | Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns | completed | — | 161 | PfizerINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04776083 | Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients | completed | Phase 3 | 75 | Menoufia UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05902260 | The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC(NutriCim) | completed | N/A | 51 | Joachim Aerts, MD PhDOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585189 | CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | completed | — | 304 | Aetion, Inc.OTHER | 0 | Sep 5, 2024 | clinicaltrials |
| NCT03172156 | ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS | completed | — | 100 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT00651833 | Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT00652561 | Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 57 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT02492867 | A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | completed | N/A | 49 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT02664181 | Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial(PRECISE) | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT03971474 | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | completed | Phase 2 | 166 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04173507 | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | completed | Phase 2 | 47 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 3, 2024 | clinicaltrials |
| NCT05794698 | Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014) | completed | — | 827 | Fudan UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04385368 | Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)(MERMAID-1) | completed | Phase 3 | 89 | AstraZenecaINDUSTRY | 33 | Aug 30, 2024 | clinicaltrials |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT03664024 | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)(KEYNOTE-782) | completed | Phase 2 | 118 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 22, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02520778 | Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02420314 | Pharmacological Ascorbate for Lung Cancer | completed | Phase 2 | 55 | Joseph J. Cullen, MD, FACSOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04764214 | SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs | completed | Phase 2 | 61 | Fudan UniversityOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT04761783 | BESPOKE Study of ctDNA Guided Immunotherapy | completed | — | 290 | Natera, Inc.INDUSTRY | 1 | Aug 15, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 23, 2024source: clinicaltrials